Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vesatolimod

- PMLiVE

Gilead and Aelix join forces to pursue HIV ‘cure’

The HTI vaccine could replace antiretroviral therapy if it reaches market

- PMLiVE

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen and Gilead combination first to reach patients

- PMLiVE

Gilead and Galapagos JAK contender scores in RA trial

Trial adds to rivalry with AbbVie

- PMLiVE

Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team

The latest industry movers

Gilead Sciences

Gilead, Galapagos JAK inhibitor clears phase II test

Hopes to compete with already-marketed drugs from Pfizer and Eli Lilly

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

The race for a HIV ‘cure’

Supercharging therapies as pharma and patients work together

- PMLiVE

ViiV chalks up another win for two-drug HIV regimen

Once a month injection matches triple oral therapy

- PMLiVE

Daily Brief: another departure at Gilead, veteran researcher to head up Karuna

Exodus continues from Gilead

- PMLiVE

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

News from pharma, biotech and healthcare

- PMLiVE

GSK two-drug trial in untreated HIV raises Gilead rivalry

Intends to file the combination later this year to challenge Gilead’s Biktarvy

- PMLiVE

Daily Brief: Janssen’s HIV vaccine, Q2 results, Biogen’s Alzheimer’s data

News from pharma, biotech and healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links